BioVie Inc (BIVI)

[someconcerns]

From a Seeking Alpha article (sorry about the formatting, but ink s below):

U.S. IPO Calendar

Issuer
Business


Deal Size
Market Cap


Price Range
Shares Filed


Top
Bookrunners

BioVie
Los Angeles, CA


$15M
$77M


$11.44
1,311,189


ThinkEquity

Early stage biotech developing therapies for cirrhosis.

BioVie, an early stage biotech developing therapies for cirrhosis, plans to raise $15 million by offering 1.3 million shares at a price of $11.44. At that price, it would command a market value of $77 million. The Los Angeles, CA-based company was founded in 2013, and plans to list on the Nasdaq under the symbol BIVI. ThinkEquity is the lead bookrunner on the deal. It is currently listed on the OTC under the symbol BIVI.

https://seekingalpha.com/article/4284339-u-s-ipo-week-ahead-kansas-bank-chinese-fintech-wrap-summer-ipo-market?ifp=1&app=1